A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Rituximab 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle

Cyclophosphamide 750mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle

Doxorubicin 50mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle

Vincristine 1.4mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle

Prednisolone 100mg orally on Days 1-5 of every 21-day cycle

Glofitamab will be administered by IV infusion as per the schedule specified in the respective arm

Polatuzumab 1.8mg/kg administered by IV infusion on Day 1 of every 21-day cycle